Osprey picks up $3.8M more for immune disease treatments
Osprey Pharmaceuticals, a drug maker focusing on inflammatory and immune disease medications, added $3.8 million to its first round of funding, bringing its total to $14.8 million, according to VentureWire. The San Francisco company says the new money was needed to see its lead drug candidate through clinical trials. It did not disclose its recent investors.
Osprey has focused its resources on a drug that could treat inflammatory kidney disease. Results from its clinical trials are… Continue Reading